CAMP (Camp4 Therapeutics) Net Margin %: -1,884.77% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAMP Camp4 Therapeutics Corp CAMP
8 GF Score
Price $4.49
! 4 Warning Signs
View Full Analysis

What is Camp4 Therapeutics Net Margin %?

Camp4 Therapeutics CAMP +0.67% 8 Net Margin % is -1,884.77% as of Jun. 2026. GuruFocus rates CAMP with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Camp4 Therapeutics ranks worse than 86.23% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Camp4 Therapeutics's Net Income for the three months ended in Jun. 2026 was $-33.53 Mil. Camp4 Therapeutics's Revenue for the three months ended in Jun. 2026 was $1.78 Mil. Therefore, Camp4 Therapeutics's net margin for the quarter that ended in Jun. 2026 was -1,884.77%.

The historical rank and industry rank for Camp4 Therapeutics's Net Margin % or its related term are showing as below:

CAMP' s Net Margin % Range Over the Past 10 Years
Min: -14083.14   Med: -7943.4   Max: -2298.54
Current: -2543.74

CAMP's Net Margin % is ranked worse than
86.23% of 944 companies
in the Biotechnology industry
Industry Median: -76.745 vs CAMP: -2543.74

Camp4 Therapeutics  (NAS:CAMP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Camp4 Therapeutics Net Margin % Related Terms

Camp4 Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Camp4 Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camp4 Therapeutics Net Margin % Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 -14,083.14 -7,943.40 -2,298.54

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -840.81 -1,899.25 -11,575.86 -1,416.62 -1,884.77

CAMP vs ALEC, ORMP, PYXS: Net Margin % Comparison

For the Biotechnology subindustry, Camp4 Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Camp4 Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's Net Margin % falls into.


CAMP
8GF Score
Camp4 Therapeutics Corp CAMP
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camp4 Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Camp4 Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-80.403/3.498
=-2,298.54 %

Camp4 Therapeutics's Net Margin for the quarter that ended in Jun. 2026 is calculated as

Net Margin=Net Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-33.53/1.779
=-1,884.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -1,884.77% mean?
Camp4 Therapeutics (CAMP) has a Net Margin % of -1,884.77% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Camp4 Therapeutics and its competitors. According to the industry distribution chart, Camp4 Therapeutics ranks #814 out of 944 companies in the Biotechnology industry, placing it in the top 86.2%.
Is Camp4 Therapeutics' Net Margin % too high?
Camp4 Therapeutics' current Net Margin % is -1,884.77%. Based on the distribution chart, Camp4 Therapeutics ranks #814 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Camp4 Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Camp4 Therapeutics' Net Margin % compare to ALEC and ORMP?
According to the Biotechnology industry distribution chart, Camp4 Therapeutics ranks #814 out of 944 companies for Net Margin %. This places Camp4 Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Camp4 Therapeutics and its competitors. Camp4 Therapeutics's current Net Margin % is -1,884.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camp4 Therapeutics stock overvalued right now?
Camp4 Therapeutics (CAMP) has a current Net Margin % of -1,884.77%. The current Net Margin % is -1,884.77%. Camp4 Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Camp4 Therapeutics (CAMP), the current Net Margin % is -1,884.77% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Camp4 Therapeutics Business Description

Address One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA, 02139
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
8GF Score

Get the complete analysis for CAMP

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.49
Price